We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+6.01%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$195M
AUM Growth
+$1.58M
Cap. Flow
-$2.25M
Cap. Flow %
-1.15%
Top 10 Hldgs %
32.39%
Holding
95
New
32
Increased
19
Reduced
11
Closed
27

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$7.51M
2
SPNC
Spectranetics Corp
SPNC
+$6.98M
3
PFE icon
Pfizer
PFE
+$4.9M
4
SYK icon
Stryker
SYK
+$4.74M
5
ABBV icon
AbbVie
ABBV
+$3.75M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$9.93M
2
BSX icon
Boston Scientific
BSX
+$5.18M
3
HUM icon
Humana
HUM
+$4.9M
4
CNMD icon
CONMED
CNMD
+$4.72M
5
AGN
Allergan plc
AGN
+$3.24M

Sector Composition

Rank Sector Weight
1 Healthcare 70.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNXP icon
51
Tonix Pharmaceuticals
TNXP
$201M
– –
0
– –
FEIC
52
DELISTED
FEI COMPANY
FEIC
$1.29M 0.66%
+15,000
New +$1.2M
IRWD icon
53
Ironwood Pharmaceuticals
IRWD
$669M
$1.04M 0.53%
+119,400
New +$1.39M
IPXL
54
DELISTED
Impax Laboratories, Inc.
IPXL
$1.04M 0.53%
+21,543
New +$1.02M
NDRM
55
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.01M 0.51%
+53,000
New +$746K
ZGNX
56
DELISTED
Zogenix, Inc.
ZGNX
$978K 0.5%
6,328
-34,297
-84% -$420K
PTCT icon
57
CALL
PTC Therapeutics
PTCT
$6.23B
$722K 0.37%
15,000
– –
CBAY
58
DELISTED
Cymabay Therapeutics
CBAY
$602K 0.31%
+200,000
New +$821K
DYAX
59
DELISTED
DYAX CORPORATION
DYAX
$554K 0.28%
+22,500
New +$596K
ALDX icon
60
Aldeyra Therapeutics
ALDX
$91.1M
$511K 0.26%
+57,500
New +$496K
OCRX
61
DELISTED
Ocera Therapeutics, Inc.
OCRX
$460K 0.24%
117,419
+42,419
+57% +$163K
DMK
62
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$337K 0.17%
1,150
– –
ARAY icon
63
CALL
Accuray
ARAY
$34.9M
$319K 0.16%
+50,000
New +$372K
KALV
64
DELISTED
KalVista Pharmaceuticals
KALV
$276K 0.14%
+2,857
New +$283K
EVAR
65
DELISTED
Lombard Medical, Inc.
EVAR
$216K 0.11%
52,875
– –
SRPT icon
66
CALL
Sarepta Therapeutics
SRPT
$1.81B
$164K 0.08%
5,400
– –
STAA icon
67
STAAR Surgical
STAA
$1.25B
$151K 0.08%
+17,204
New +$160K
ABT icon
68
CALL
Abbott
ABT
$188B
– –
-150,000
Closed -$6.95M
ANGO icon
69
AngioDynamics
ANGO
$651M
– –
-125,000
Closed -$2.22M
BAX icon
70
CALL
Baxter International
BAX
$14.4B
– –
-460,250
Closed -$17.1M
BAX icon
71
Baxter International
BAX
$14.4B
– –
-266,945
Closed -$9.93M
CI icon
72
CALL
Cigna
CI
$73.6B
– –
-20,000
Closed -$2.59M
CNMD icon
73
CONMED
CNMD
$1.48B
– –
-93,405
Closed -$4.72M
DHR icon
74
CALL
Danaher
DHR
$147B
– –
-37,196
Closed -$2.12M
ESPR
75
DELISTED
Esperion Therapeutics
ESPR
– –
-20,000
Closed -$1.96M
1 2
3
4

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q2 2015 Portfolio in Review

As of Q2 2015, Pura Vida Investments held 95 positions worth $195M, up 0.82% from $194M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Pura Vida Investments's Q2 2015 filing shows 32 new, 19 increased, 11 reduced and 27 closed positions. Its largest new stake was Universal Health Services: 60,000 shares worth $8.71M. The largest sale was Baxter International, an estimated $9.93M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 55% a quarter earlier.

  • Pura Vida Investments's largest Q2 2015 buy was Universal Health Services: 60,000 shares worth $8.71M.
  • Pura Vida Investments added most to Cigna in Q2 2015, an estimated $3.59M increase.
  • Pura Vida Investments's biggest Q2 2015 reduction was Boston Scientific, cutting an estimated $5.18M.
  • Pura Vida Investments fully exited Baxter International in Q2 2015, selling an estimated $9.93M.
  • Pura Vida Investments's ten largest holdings make up 32% of its $195M portfolio in Q2 2015.
  • Pura Vida Investments opened 32 new positions and closed 27 in Q2 2015.
  • Pura Vida Investments's portfolio value rose 0.82% quarter-over-quarter to $195M.

Based on Pura Vida Investments's 13F filing for Q2 2015, filed 14 Aug 2015.